MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum
Open Access
- 3 February 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 17 (2), e1009283
- https://doi.org/10.1371/journal.ppat.1009283
Abstract
The frequent overexpression of CD46 in malignant tumors has provided a basis to use vaccine-lineage measles virus (MeV) as an oncolytic virotherapy platform. However, widespread measles seropositivity limits the systemic deployment of oncolytic MeV for the treatment of metastatic neoplasia. Here, we report the development of MeV-Stealth, a modified vaccine MeV strain that exhibits oncolytic properties and escapes antimeasles antibodies in vivo. We engineered this virus using homologous envelope glycoproteins from the closely-related but serologically non-cross reactive canine distemper virus (CDV). By fusing a high-affinity CD46 specific single-chain antibody fragment (scFv) to the CDV-Hemagglutinin (H), ablating its tropism for human nectin-4 and modifying the CDV-Fusion (F) signal peptide we achieved efficient retargeting to CD46. A receptor binding affinity of ~20 nM was required to trigger CD46-dependent intercellular fusion at levels comparable to the original MeV H/F complex and to achieve similar antitumor efficacy in myeloma and ovarian tumor-bearing mice models. In mice passively immunized with measles-immune serum, treatment of ovarian tumors with MeV-Stealth significantly increased overall survival compared with treatment with vaccine-lineage MeV. Our results show that MeV-Stealth effectively targets and lyses CD46-expressing cancer cells in mouse models of ovarian cancer and myeloma, and evades inhibition by human measles-immune serum. MeV-Stealth could therefore represent a strong alternative to current oncolytic MeV strains for treatment of measles-immune cancer patients.Keywords
Funding Information
- Al and Mary Agnes McQuinn
- Mayo Clinic
This publication has 93 references indexed in Scilit:
- Lethal Canine Distemper Virus Outbreak in Cynomolgus Monkeys in Japan in 2008Journal of Virology, 2013
- Canine Distemper Virus Epithelial Cell Infection Is Required for Clinical Disease but Not for ImmunosuppressionJournal of Virology, 2012
- Envelope-chimeric Entry-targeted Measles Virus Escapes Neutralization and Achieves OncolysisMolecular Therapy, 2011
- Expression of the Sendai (murine parainfluenza) virus C protein alleviates restriction of measles virus growth in mouse cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccineVaccine, 2011
- Conformational Changes of the HIV-1 Envelope Protein during Membrane Fusion Are Inhibited by the Replacement of Its Membrane-spanning DomainOnline Journal of Public Health Informatics, 2010
- Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy ModelClinical Cancer Research, 2009
- Protein Kinase PKR Mediates the Apoptosis Induction and Growth Restriction Phenotypes of C Protein-Deficient Measles VirusJournal of Virology, 2009
- Dynamic Interaction of the Measles Virus Hemagglutinin with Its Receptor Signaling Lymphocytic Activation Molecule (SLAM, CD150)Online Journal of Public Health Informatics, 2008
- Affinity Thresholds for Membrane Fusion Triggering by Viral GlycoproteinsJournal of Virology, 2007